Stock Events

Stock Events

Coherus Oncology 

$1.3900
104
-$0.01-0.71% Tuesday 02:08

Statistics

Day High
1.39
Day Low
1.39
52W High
1.85
52W Low
1.36
Volume
4
Avg. Volume
-
Mkt Cap
214.76M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

9NovExpected
Q3 2025
Q1 2026
Q2 2026
Next
-0.35
-0.31
-0.26
-0.22
Expected EPS
-0.219159
Actual EPS
N/A

Financials

141.45%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
118.79MRevenue
168.02MNet Income

Analyst Ratings

$10.00Average Price Target
The highest estimate is 10.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CHRS.BOATS. It's not an investment recommendation.
Microsoft
16
MSFT
Tesla
16
TSLA
Realty Income
15
O
NVIDIA
15
NVDA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap204.01B
Amgen is a biotech company that competes with Coherus in the biosimilars and biologics market, particularly in areas like oncology and inflammation.
Pfizer
PFE
Mkt Cap157.99B
Pfizer has a strong presence in the biosimilars market, directly competing with Coherus Biosciences in developing and marketing biosimilar versions of blockbuster drugs.
Syndax Pharmaceuticals
SNDX
Mkt Cap1.62B
Syndax Pharmaceuticals is involved in developing therapies that could compete with Coherus's oncology portfolio, particularly in breast cancer treatments.
Merck
MRK
Mkt Cap355.1B
Merck competes with Coherus in the oncology sector, with a strong pipeline of cancer treatments that could rival Coherus's offerings.
Bristol-Myers Squibb
BMY
Mkt Cap130B
Bristol Myers Squibb has a diverse range of oncology products that compete with Coherus's cancer treatment portfolio.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap43.22B
Teva Pharmaceutical Industries is a key player in the generic and biosimilar drugs market, making it a direct competitor to Coherus in several therapeutic areas.
Abbvie
ABBV
Mkt Cap454.36B
AbbVie competes with Coherus in the biologics market, especially with their shared focus on autoimmune diseases and biosimilars.
Biogen
BIIB
Mkt Cap32.08B
Biogen's focus on innovative biologics in areas like neurology and autoimmune diseases puts it in competition with Coherus's biosimilar and novel biologic products.
Regeneron Pharmaceuticals
REGN
Mkt Cap80.46B
Regeneron Pharmaceuticals competes in the biologics space, particularly in ophthalmology and rheumatology, areas where Coherus is also aiming to make an impact.
Novartis
NVS
Mkt Cap260.7B
Novartis, through its generics division Sandoz, is a major player in the biosimilars market, competing directly with Coherus in offering lower-cost versions of biologic drugs.

About

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
Show more...
CEO
ISIN
US19249H1032

Listings

STU
DE
8C5.STU
F
DE
8C5.F
MU
DE
8C5.MU
BOATS
BOATS
CHRS.BOATS

0 Comments

Share your thoughts

FAQ

What is Coherus Oncology stock price today?▼
The current price of CHRS.BOATS is $1.39 USD — it has decreased by -0.71% in the past 24 hours. Watch Coherus Oncology stock price performance more closely on the chart.
What is Coherus Oncology stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boats exchange Coherus Oncology stocks are traded under the ticker CHRS.BOATS.
What is Coherus Oncology market cap?▼
Today Coherus Oncology has the market capitalization of 214.76M
When is the next Coherus Oncology earnings date?▼
Coherus Oncology is going to release the next earnings report on November 09, 2026.
What were Coherus Oncology earnings last quarter?▼
CHRS.BOATS earnings for the last quarter are -0.22 USD per share, whereas the estimation was -0.25 USD resulting in a +12% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Coherus Oncology revenue for the last year?▼
Coherus Oncology revenue for the last year amounts to 118.79M USD.
What is Coherus Oncology net income for the last year?▼
CHRS.BOATS net income for the last year is 168.02M USD.
In which sector is Coherus Oncology located?▼
Coherus Oncology operates in the Other sector.
When did Coherus Oncology complete a stock split?▼
Coherus Oncology has not had any recent stock splits.